Pfizer 3Q Earnings Powered by Oncology, Beat Estimates

Eagle Eye Opener

Pfizer

Pfizer 3Q Earnings Powered by Oncology, Beat Estimates (Reuters)

The United States’ largest drug maker, Pfizer Inc., reported that Q3 earnings beat estimates. The company earned $2.59 billion for the quarter, or 58 cents per share (excluding special items), while analysts had predicted 56 cents per share. Much of the additional profit came from a 26 percent pop in oncology drug sales, which totaled $407 million for the quarter. However, global sales for the period fell 7 percent to $12.64, due to generic competition for Lipitor and other drugs. Wall Street had expected sales of $12.7 billion. Investors in Pfizer now have to ask themselves if they can see momentum continuing at that fervid pace for oncology drugs, and if that will be enough to overcome lagging global sales. If you come up with a good answer, please let us know by commenting below.

Exclusive  Three Data Center Stocks to Buy Emerge as Promising Ways to Profit
share on:

Like This Article?
Now Get Mark's FREE Special Report:
3 Dividend Plays with Sky-High Returns

This newly-released report by a top-20 living economist details three investments that are your best bets for income and appreciation for the rest of the year and beyond.

Get Access to the Report, 100% FREE


img
previous article

Deutsche Bank AG, Europe’s largest bank by revenue, reported its third-quarter profit fell by 94 percent.

share on:

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

  • Forecasts & Strategies
  • Home Run Trader
  • Fast Money Alert
  • Five Star Trader
  • TNT Trader
LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

  • Cash Machine
  • Premium Income (exclusively for subscribers of Cash Machine)
  • Quick Income Trader
  • Breakout Profits Alert
  • Hi-Tech Trader
LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

  • Successful Investing
  • Intelligence Report
  • Bullseye Stock Trader
LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

  • Retirement Watch
  • Retirement Watch Spotlight Series
  • Lifetime Retirement Protection Program
LEARN MORE HERE

Jon Johnson

Jon Johnson's philosophy in investing and trading is to take what the market gives you regardless if that is to the upside or downside. For the past 21 years, Jon has helped thousands of clients gain success in the financial markets through his newsletters and education services:

Product Details

  • Investment House Daily
  • Technical Traders Alert
  • Success Trading Group
LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

  • Dividend Investor
LEARN MORE HERE